# CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Source: https://onco.cc/trials/nct04495153/  
OnCo record `nct04495153` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Aglatimagene besadenovec in non-small-cell lung cancer and small-cell lung cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.

## Summary

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC is a phase 2 interventional study registered as NCT04495153 by Candel Therapeutics, Inc., with 90 participants enrolled, started 2020-10-13 and due to reach its primary completion in 2024-12-31. Interventions recorded: Aglatimagene besadenovec. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04495153
- Phase: 2
- Setting: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
- Sponsor: Candel Therapeutics, Inc.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT04495153: https://clinicaltrials.gov/study/NCT04495153

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Aglatimagene besadenovec](https://onco.cc/drugs/aglatimagene-besadenovec/)
- companies: [Candel Therapeutics](https://onco.cc/companies/candel-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04495153.json